Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD.

Molecular oncology - 1 Jul 2023

Qian Yu, Zhang Xiang, Mao Shihui, Wei Wenwen, Lin Xiangjie, Ling Qing, Ye Wenle, Li Fenglin, Pan Jiajia, Zhou Yutong, Zhao Yanchun, Huang Xin, Huang Jiansong, Tong Hongyan, Sun Jie, Jin Jie

Abstract excerpt

Bromodomain-containing protein 4 (BRD4) inhibitors have been clinically developed to treat acute myeloid leukemia (AML), but their application is limited by the possibility of drug resistance, which is reportedly associated with the activation of the WNT/β-catenin pathway. Meanwhile, homoharringtonine (HHT), a classic antileukemia drug, possibly inhibits the WNT/β-catenin pathway. In this study, we attempted to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to beta Catenin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Nuclear Proteins

Share to Protein Kinase Inhibitors

Share to Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 36567628
DOI: 10.1002/1878-0261.13368
PMCID: PMC10323884

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD.PMID 36567628Read ↗

The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia.Semantic proximity Read ↗

A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia CellsSemantic proximity Read ↗

Bortezomib synergizes with homoharringtonine in FLT3-ITD-relapsed/refractory acute myeloid leukemia by inducing FLT3-ITD protein degradation.Semantic proximity Read ↗

Synergistic Effect of Chidamide and Venetoclax on Apoptosis in Acute Myeloid Leukemia Cells and Its MechanismSemantic proximity Read ↗

Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmCSemantic proximity Read ↗

Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of ResistanceSemantic proximity Read ↗

P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.Semantic proximity Read ↗

BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid LeukemiaSemantic proximity Read ↗

Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.Semantic proximity Read ↗

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell linesSemantic proximity Read ↗

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell linesSemantic proximity Read ↗

Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanismSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.